Member Info for SamJSung

Pulsiv .modules, specifically Pulsiv OSMIUM technology, are receiving positive feedback for their efficiency, thermal performance, and ability to simplify power supply design, particularly in compact and heat-sensitive applications like USB-C chargers. They are also enabling smaller, lighter, and more cost-effective designs.

Here's a more detailed look:

Key Benefits:

High Efficiency:

Pulsiv OSMIUM achieves high peak (99.5%) and average (97.5%) front-end efficiency, with a flat efficiency profile across the load range.

Improved Thermal Performance:

Pulsiv's reference design for 65W USB-C demonstrates significantly reduced component temperatures, potentially enabling compact and heat-sensitive applications like in-wall USB-C sockets.

Reduced Component Count and Size:

The technology allows for smaller and lower voltage components, potentially leading to smaller overall power supply designs.

Eliminated Input Voltage Derating and Inrush Current:

Pulsiv OSMIUM addresses these common challenges in power supply design.

Simplified Design:

Pulsiv provides reference designs, standard assembled modules, and custom module options to simplify the design process for various applications.

Increased Flexibility:

The technology enables a single PSU to support multiple applications, previously requiring optimized PSUs.

Examples of Positive Feedback:

The PSMA Energy Management Committee recognized Pulsiv with the 2025 Global Energy Efficiency Award for its 65W USB-C reference design.

Salom, a leading consumer electronics PSU maker, is using Pulsiv OSMIUM MCUs in their new 150W PSU flyback platform and noted its high efficiency and flat efficiency profile.

Andy Richardson, Salom's VP of Business Development, highlighted that the technology delivers "an astonishing flat efficiency profile with no inrush current".

Astute Electronics, a distributor, expanded their partnership with Pulsiv, citing the technology's disruptive nature and their confidence in its potential.

Future Outlook:

Pulsiv is expanding its technology to a broader range of applications beyond USB-C, including solar and other power electronics.

The company is offering various deployment options, including reference designs, standard assembled modules, and custom modules.

Pulsiv expects to redefine the fast-charging space and is focused on delivering its technology to a wider customer base.

Let us not forget that Simon Oakes, Chief Financial Officer who is still in post allowed the smoke and mirrors to be maintained for a substantial period of time with his CEO Adrian Biles. I can only assume that Oakes is in post only until BDO have finished their Audit. His usefulness must be because he probably knows where the "Bodies" are hidden / buried. Otherwise why is he still there ?

A classic Ince Shambles....

With Simon Oakes (Chief Financial Officer) " Significant" share holding of 27,777 shares worth currently approx £1400 it should be at the top of Donald Brown's must do list to find a dynamic competent replacement to help re-engineer the merged company of Arden and Ince. Oakes is also tainted by association with the failed Biles strategy and a board clearout should enable DB to move quickly with a new team and a new strategy.

532,498 shares in the share capital of Belluscura at an exercise price of 6.5 pence. The consideration for the exercise of these share options amounts, in aggregate, to a cash value of £34,612.37.

It is £34, 612.47 (6.5p X 532,498) that is the cash Value payable to exercise options on 532498 shares.

As an avid reader of this BT Board.. Some observations
An RNS on the 3rd August included in Director Transactions the following regarding Marc Allera, CEO Consumer..
VESTING AND SALE OF 115,742 SHARES UNDER THE BT GROUP DEFERRED BONUS PLAN AND VESTING AND SALE OF 178,861 SHARES UNDER THE BT GROUP INCENTIVE SHARE PLAN. Note: No share Retentions likewise with the award to HARMEEN MEHTA ..Also no Retentions.

What I find interesting is that their boss P J must have been aware of their intentions and did not or could not change their mind regarding just selling enough to cover tax due...PJ must have recognised the impact both these actions would have caused... so why did he allow this with these two individuals who are in critical posts in BT? especially by Marc Allera? Thoughts would be appreciated !

Part of the reason of why the drop has / is occurring MAY lie in the following comment made on the ADVFN Board..
40 Fathoms 9 Dec '21 -

I am not sure the volume was so large yesterday. But nevertheless we know that Allianz are in the process of finishing their sell down. They ended the 3rd quarter with 4,000,000 shares and are last reported at 752,500 shares. They have been responsible for a significant part of the recent pressure on the shareprice, but another week or so and they should be done.

I have also asked the question from Investor relations...
The reply I received this morning :-

"Your concerns have been shared with our Directors who continue to be focussed on restoring trading in Ince ordinary shares as soon as may be possible.
The company is obliged to inform the market via an announcement and will do that as soon as there is new information to share.
Thank you for your patience".

Keep an eye on BT’s French fox
BT reports half-year results on Thursday. Analysts will be watching the pace of plans to roll out full-fibre broadband to 25 million premises given the threat of increased competition from the merged Virgin Media O2. But the real point of interest will be lurking in the background: Patrick Drahi. The French-Israeli mogul swooped on a stake in BT of just over 12 per cent in June, vowing at the same time not to make a bid for six months. That pledge expires on December 10. While few expect him to pop up with a bid the next day, Drahi has made clear in conversations with industry insiders that he wants to own BT, particularly its Openreach broadband subsidiary.

The company is on alert for a range of scenarios, including possible demands for a break-up, and has hired advisory firm Robey Warshaw alongside Goldman Sachs. It is already in the process of selling its sports broadcasting business, with billionaire Len Blavatnik’s DAZN streaming service seen as frontrunner.

Likelier than an immediate outright bid is more stakebuilding from Drahi, who moves with fox-like stealth. He will know that a takeover of BT by a secretive tycoon based in Switzerland would put the government under intense pressure to intervene. He may test the waters by upping his stake towards the 30 per cent mandatory bid threshold first.

If he does, we probably won’t know about it until it’s announced. He has a taste for manoeuvering with derivatives. This situation is one to keep an eye on.

oliver.shah@sunday-times.co.uk

25-Aug-21 18:18:14 59.90 1,809,999 Unknown*
25-Aug-21 17:30:11 60.20 1,809,999 Buy*
It looks like a matched buy / sell with the difference being commission to the market maker..Possibly a move from one major holder to another...

A hypothetical perspective.. If you take Link Fund Solutions 17.7% of SNG ( which I suspect is available at the right Price) and Richard Griffiths 12.2% (adjusted for the increase in share capital) which I believe has been sold in its entirety .. there is a 29.9% perspective stake in SNG available to a prospective bidder.. All Hypothetical of course . The next few weeks will be very interesting.

Usually when a TR-1 is issued showing a remaining holding less than 3% it means that Griffiths has sold out his complete stake... A personal view

Trek... This was going through my mind... With Pressure on Link to return cash to Woodford Investors ( They had the Woodford Holding transferred back to them on the 17th October 2019) they have held tight with a substantial holding and not sold a single share, even though SNG has risen substantially from lows of about 6p to current 61p . They must be strong believers in the future.. !

Link Fund Solutions are currently recorded as holding 21,341,293shares equal to 19.5% of the current issued share capital..
Whilst both Richard Griffiths and Leonard Licht have reduced their holdings … possibly to rise again after the completion of the Fund Raise.. It raises the question what is the future of Link Fund Solutions holding.. It is very unlikely they will be subscribing to any new shares (they need to be liquidating their holdings not adding to repay holders of Woodford Trusts)
No TR-1 has been issued to show ANY reduction implying none of their holding has been sold..

Link's holding is likely to be a good platform for any possible future bid, they may have received bids for their holding but holding out for better terms...but for how long can they hold out for when the liquidators of Woodford need more capital to refund holders and soon. .Astra would / could buy this holding or already have put an option in place to acquire their holding .. if nothing else to stop a full scale bid for SNG from others.
Or can we expect a continuous sale of their SNG shares over the next few days / weeks leading up to the outcome of the SNG001 trial..

It is worth also noting the following :-
In addition, Lansdowne Partners Ltd ("Lansdowne") is a substantial shareholder in the Company holding 10 per cent. or more of the existing issued Ordinary Shares and has agreed to subscribe for 4,285,714 Placing Shares at the Issue Price, representing 10.7 per cent. of the total New Ordinary Shares.

Leonard has reduced his holding from 10,700,000 (9.8%) (as shown on the SNG Investor Information section) to 9,720,000 ordinary shares of 1 pence each in the capital of the Company, representing 8.88% of the Company's issued share capital.

If We were to assume that Link Fund Solutions Ltd 19.5% of SNG is still intact (No TR-1 issued to say otherwise) add in the Sale of Richard Griffiths 6% there is approx. 25% of SNG available for either a large institution / Investor or as a platform for a future bid.. Time will tell .

FinnCapp who are Brokers to Synairgen (so they me be more than a little bias with their comment) do make some very interesting comments in their latest SNG update..

Synairgen (SNG): Corp COVID-19 Phase II trial to start imminently Synairgen announced that it has received expedited approvals from MHRA and HCA in the UK to conduct a Phase II trial of SNG001 (inhaled interferon beta/IFN-ß) initially in 100 hospitalised patients with mild-moderate COVID-19. This is not an insignificant challenge given the fast-moving situation for COVID-19 and positions Synairgen favourably ahead of the expected increase in COVID-19 cases in the UK. The trial is expected to commence imminently, with an initial readout likely in Q2 2020. We are putting our 54p target price, which was underpinned by the rNPV of SNG001 in COPD as well as economic interest in Pharmaxis’ LOXL2 programme, under review pending further analysis. Nevertheless, we view the potential risk-adjusted value of SNG001 as an antiviral to be very significant given the lack of therapeutics to treat COVID19.

The last Week or two has seen what I call extreme trading..
My thoughts relate to the following...
(1) Pharmaxis : No news expected on Corporate Partnering for LOXL2 until the earliest end of March 20.
(2) Preliminary statement of results for the year ended 31 December 2019 due around end of Feb 20
(3) No News expected on Part 2 of Synairgen’s Phase II clinical trial in patients with COPD until end of Q2 2020, there might be reference / update on the current trial with Preliminary statement of results around end of Feb 2020
(4) No information currently available regarding the near 20% of Neil Woodfords holding, Where is it? Who has it ? and what might become of it.. other than speculation.
(5) No TR-1 from anybody / organisation regarding adding or reducing their current holdings.. including Ex Neil Woodfords stake.
The Market Size for trading SNG shares is 10000.. I appreciate that this can be nothing more than a guide but I cannot relate to where these 6 figure trades are coming from … both buy / sells.. 100K, 125K, 150K, 200 K etc.. The sheer size of each of these trades should be enough to either send the shares to the moon or crashing to the floor.. But still these trade volumes continue..
I appreciate that Market Makers play games to both gather stock and sell stock on their books but the sheer size of some individual trades does in my mind question the reality of current trading. and yet it is happening..With dramatic swings of the SNG share price taking place.. today down nearly 10% other days closing even higher..One might assume as Rich states that there is dramatic action happening behind the scenes..this may be true but no TR1 has been issued either adding or reducing their holdings .. 3% which is the baseline for reporting a major holding would mean that any holder with approx. 3.3 million SNG shares would have to issue a TR1declaring their interest.. Yet nothing..
In summary .. we SNG shareholders have a lot to look forward to , hopefully all good news... but does the current share trading in anyway reflect pure speculation, bored private investors selling up, Market Makers shenanigans, serious purchases by parties unknown but keeping below the 3% threshold.. What I wonder do major shareholders Leonard Licht and Richard Griffiths make of current trading and volatile share price..Perhaps nothing and are more than happy with their holdings and anticipating significant future increase in the value of their holdings..!!
I am anticipating further volatility over the next few weeks.. hopefully positive to the current share price.. Any official news from any source (see 1- 5 above) will I expect have serious impact on the current share price, drive out the speculators and if positive give long term shareholders the reward they deserve.

This could be very positive for SNG holders, allowing individual bids for individual share stakes.. rather than having to purchase an entire portfolio of Biotech companies.

From Todays Sunday Times..
The Neil Woodford saga has rumbled on since the former star Invesco fund manager had to suspend his flagship £3bn income fund last June.

I'm afraid Woodford investors should brace themselves for more bad news: an attempt to sell the former star fund manager's stakes in a collection of biotech start-ups, including Immunocore and Oxford Nanopore, has failed. As our healthcare correspondent Sabah Meddings reports, WG Partners, a boutique investment bank that was trying to put together a £550m fund to buy the portfolio, has missed a crunch deadline to complete the deal. That means PJT Park Hill, the advisory firm tasked with selling off the Woodford Equity Income Fund's more illiquid assets, is likely to have to sell off the holdings piecemeal at knock-down prices, resulting in lower returns for investors trapped in the Woodford flagship, and more turbulence for the companies themselves.